Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action
Author:
Affiliation:
1. Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Publisher
American Society of Clinical Oncology (ASCO)
Subject
Cancer Research,Oncology
Link
http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2007.11.8992
Reference23 articles.
1. A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer
2. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42:101,1975-104,
3. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
4. Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
5. Girling JC, Soutter WP: Cytoreductive surgery in the primary management of advanced epithelial ovarian carcinoma: A topic for debate. Int J Gynecol Cancer 81,1996-84,
Cited by 34 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis;American Journal of Therapeutics;2022-12-20
2. Patterns of Treatment and Outcomes in Epithelial Ovarian Cancer: A Retrospective North Indian Single-Institution Experience;JCO Global Oncology;2022-11
3. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer;Cochrane Database of Systematic Reviews;2022-08-30
4. Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer;Cancer;2019-08-27
5. Survival of advanced epithelial ovarian/fallopian tube/primary peritoneum carcinoma after high-complexity upper abdominal surgery;European Journal of Gynaecological Oncology;2019
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3